Topiramat – przegląd wybranych artykułów

• Authors: Andrzej Klimek

Title variants

EN

Topiramate – review of selected papers

• Languages of publication: PL

Abstracts

PL

Padaczka stanowi poważny problem epidemiologiczny z powodu znacznego rozpowszechnienia, a także terapeutyczny ze względu na odsetek przypadków lekooporności wynoszący 30%. W związku z tym położono nacisk na proces zsyntetyzowania nowych leków przeciwpadaczkowych (LPP), które będzie cechować większa skuteczność niż dotychczasowych. Pomimo wprowadzenia do obrotu ponad dziesięciu LPP drugiej generacji odsetek przypadków padaczki lekoopornej nie uległ zmianie, aczkolwiek u pojedynczych chorych wykazały one wyższość nad preparatami stosowanymi tradycyjnie. Do leków przeciwpadaczkowych drugiej generacji należy między innymi topiramat (TPM), cechujący się unikalną budową chemiczną (pochodna fruktopiranozy). W Polsce został wprowadzony do obrotu w 1998 roku. W niniejszej pracy opisano właściwości farmakokinetyczne, jak również zastosowanie TPM jako terapii dodanej w napadach padaczkowych uogólnionych i napadach częściowych oraz jako monoterapii w tego typu napadach. Topiramat ma wielokierunkowy mechanizm działania. Jest silnym blokerem kanałów sodowych, a także wpływa na kanały wapniowe, zwiększa aktywność receptorów GABA, blokuje typ kainowy/AMPA receptorów glutaminowych, jest słabym inhibitorem anhydrozy węglanowej. Omówiono dodatkowo możliwości zastosowania TPM w status epilepticus. Zwrócono uwagę na koszt leczenia topiramatem w porównaniu z takimi lekami, jak kwas walproinowy, oraz wpływ na jakość życia w porównaniu na przykład z lamotryginą. Opisano objawy uboczne, przyglądając się bliżej przyczynie spadku wagi przy zastosowaniu TPM oraz możliwości wystąpienia kwasicy metabolicznej, kamicy nerkowej oraz zmniejszonej potliwości. Podkreślono zalety stosowania topiramatu na tle innych LPP.

EN

Epilepsy is one of the most wide spread and serious paroxysmal disorders as well as 30% cases of resistant epilepsy. Topiramate (TPM) is one of many drugs of the second generation. Topiramate, a sulfonatesubstituted derivative of the monosacharide D-fructose, has been associated with a broad spectrum of antiepileptic activity. The precise mechanism of TPM is unknown, is considered that TPM produce antiepileptic effects through enhancement of GABA-erge activity, inhibition of kainate/AMAP glutamate receptors, inhibition of voltage- sensitivite sodium and calcium channel, increases in potasium conductance and inhibition of carbonic anhydrase. Oral TPM is rapidly absorbed in patients with epilepsy with a relative bioavailability of near 80%. In many clinical trials, appeareddosages (i.e. 200 mg b.d.) of topiramate as monotherapy or adjunctive therapy were effective in reducing the frequency of seizures in patients with primary generalised tonic-clonic seizures, partial seizures. The cost-utility analysis included direct medical and social services cost in the UK, TPM was predicted to be cost-effective relative to standard treatment with valproic acid in adults with generalised or unclassified epilepsy cross a range of thresholds for the cost per quality-adjusted life-year (QALY) gained as was preferred over lamotrigine. However, in adults with partial epilepsy, lamotrigine appeared to be cost-effective relative to standard treatment with carbamazepine over gabapentin and topiramate. Treatment with topiramate is commonly associated with adverse events, among others especially with weight-loss and cognitive dysfunction. The carbonic anhydrase inhibitory effects of TPM may result in metabolic acidosis, renal calculi and hypohidrosis.

Keywords

EN

adverse events; epilepsy; farmakokinetyka; objawy uboczne; padaczka; pharmacokinetic properties; skuteczność działania; therapeutic efficacy; topiramat; topiramate

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Aktualności Neurologiczne
• Year: 2013
• Volume: 13
• Issue: 2
• Pages: 88–95

Contributors

author

Andrzej Klimek

• Klinika Neurologii i Epileptologii z Oddziałem Udarowym Katedry Chorób Układu Nerwowego UM

References

• 1. Zwoliński P.: Topiramat. W: Jędrzejczak J., Zwoliński P. (red.): Nowe leki przeciwpadaczkowe. Fundacja Epileptologii, Warszawa 2000: 60–72.
• 2. Kuzniecky R., Hetherington H., Ho S. i wsp.: Topiramate increases cerebral GABA in healthy humans. Neurology 1998; 51: 627–629.
• 3. Shank R.P., Gardocki J.F., Streeter A.J., Maryanoff B.E.: An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41 supl. 1: S3–S9.
• 4. Dodgson S.J., Shank R.P., Maryanoff B.E.: Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000; 41 supl. 1: S35–S39.
• 5. Kaminski R.M., Banerjee M., Rogawski M.A.: Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004; 46: 1097–1104.
• 6. Langtry H.D., Gillis J.C., Davis R.: Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997; 54: 752–773.
• 7. Johannessen S.I.: Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsia 1997; 38 supl. 1: S18–S23.
• 8. Bialer M., Doose D.R., Murthy B. i wsp.: Pharmacokinetic interactions of topiramate. Clin. Pharmacokinet. 2004; 43: 763–780.
• 9. Lyseng-Williamson K.A., Yang L.P.: Topiramate: a review of its use in the treatment of epilepsy. Drugs 2007; 67: 2231–2256.
• 10. Johannessen Landmark C., Baftiu A., Tysse I. i wsp.: Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. Ther. Drug Monit. 2012; 34: 440–445.
• 11. Battino D., Croci D., Rossini A. i wsp.: Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clin. Pharmacokinet. 2005; 44: 407–416.
• 12. Privitera M., Fincham R., Penry J. i wsp.: Topiramate placebo- controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Topiramate YE Study Group. Neurology 1996; 46: 1678–1683.
• 13. Faught E., Wilder B.J., Ramsay R.E. i wsp.: Topiramate placebo- controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996; 46: 1684–1690.
• 14. Sachdeo R.C., Reife R.A., Lim P. i wsp.: Topiramate monotherapy for partial onset seizures. Epilepsia 1997; 38: 294–300.
• 15. Reife R.A., Pledger G.W.: Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five double-blind, placebo-controlled trials. Epilepsia 1997; 38 supl. 1: S31–S33.
• 16. Biton V., Montouris G.D., Ritter F. i wsp.: A randomized, placebo- controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999; 52: 1330–1337.
• 17. Montouris G.D., Biton V., Rosenfeld W.E.: Nonfocal generalized tonic-clonic seizures: response during long-term topiramate treatment. Topiramate YTC/YTCE Study Group. Epilepsia 2000; 41 supl. 1: S77–S81.
• 18. Gilliam F.G., Veloso F., Bomhof M.A. i wsp.: A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2000; 60: 196–202.
• 19. Arroyo S., Dodson W.E., Privitera M.D. i wsp.: Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol. Scand. 2005; 112: 214–222.
• 20. Guerrini R., Carpay J., Groselj J. i wsp.: Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting. Seizure 2005; 14: 371–380.
• 21. Privitera M.D., Brodie M.J., Mattson R.H. i wsp.: Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol. Scand. 2003; 107: 165–175.
• 22. Marson A.G., Al-Kharusi A.M., Alwaidh M. i wsp.: The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomized controlled trial. Lancet 2007; 369: 1000–1015.
• 23. Marson A.G., Al-Kharusi A.M., Alwaidh M. i wsp.: The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblinded randomized controlled trial. Lancet 2007; 369: 1016–1026.
• 24. Hufnagel A., Kowalik A., Rettig K. i wsp.: Long-term assessment of topiramate for epilepsy: an open-label, single-arm, multicenter, prospective study in a naturalistic setting. Clin. Drug Investig. 2011; 31: 779–790.
• 25. Elterman R.D., Glauser T.A., Wyllie E. i wsp.: A double-blind, randomized trial of topiramate as adjunctive therapy for partial- onset seizures in children. Topiramate YP Study Group. Neurology 1999; 52: 1338–1344.
• 26. Sachdeo R.C., Glauser T.A., Ritter F. i wsp.: A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999; 52: 1882–1887.
• 27. Kowalik A., Rimpau W., Adam H. i wsp.: Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy. Acta Neurol. Scand. 2008; 117: 159–166.
• 28. Schreiner A., Stollhoff K., Ossig W. i wsp.: Conversion from valproic acid onto topiramate in adolescents and adults with epilepsy. Acta Neurol. Scand. 2009; 119: 304–312.
• 29. Guberman A., Neto W., Gassmann-Mayer C.: Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand. 2002; 106: 183–189.
• 30. Korian Topiramate Study Group: Low dose and slow titration of topiramate as adjunctive therapy in refractory partial epilepsies: a multicentre open clinical trial. Seizure 2002; 11: 255–260.
• 31. Dodson W.E., Kamin M., Kraut L. i wsp.: Topiramate titration to response: analysis of individualized therapy study (TRAITS). Ann. Pharmacother. 2003; 37: 615–620.
• 32. Peeters K., Adriaenssen I., Wapenaar R. i wsp.: A pooled analysis of adjunctive topiramate in refractory partial epilepsy. Acta Neurol. Scand. 2003; 108: 9–15.
• 33. Naritoku D.K., Hulihan J.F., Schwarzman L.K. i wsp.: Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial. Ann. Pharmacother. 2005; 39: 418–423.
• 34. Abou-Khalil B.: Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group. Epilepsia 2000; 41 supl. 1: S72–S76.
• 35. Lambrakis C.C., Lancman M.E.: The phenomenology of seizures and epilepsy after stroke. J. Epilepsy 1998; 11: 233–240.
• 36. Rowan A.J.: Reflections on the treatment of seizures in the elderly population. Neurology 1998; 51 (supl. 4): S28–S33.
• 37. Klimek A.: Padaczka jako problem wieku podeszłego. Aktualn. Neurol. 2007; 7: 141–147.
• 38. Stefan H., Hubbertz L., Peglau I. i wsp.: Epilepsy outcomes in elderly treated with topiramate. Acta Neurol. Scand. 2008; 118: 164–174.
• 39. Sommer B.R., Fenn H.H.: Review of topiramate for the treatment of epilepsy in elderly patients. Clin. Interv. Aging 2010; 5: 89–99.
• 40. Kockelmann E., Elger C.E., Helmstaedter C.: Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. Epilepsy Behav. 2004; 5: 716–721.
• 41. Fritz N., Glogau S., Hoffmann J. i wsp.: Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav. 2005; 6: 373–381.
• 42. Lee H.W., Jung D.K., Suh C.K. i wsp.: Cognitive effects of lowdose topiramate monotherapy in epilepsy patients: a 1-year follow-up. Epilepsy Behav. 2006; 8: 736–741.
• 43. Salinsky M.C., Storzbach D., Spencer D.C. i wsp.: Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 2005; 64: 792–798.
• 44. Meador K.J., Loring D.W., Vahle V.J. i wsp.: Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005; 64: 2108–2114.
• 45. Reuber M., Evans J., Bamford J.M.: Topiramate in drug-resistant complex partial status epilepticus. Eur. J. Neurol. 2002; 9: 111–112.
• 46. Towne A.R., Garnett L.K., Waterhouse E.J. i wsp.: The use of topiramate in refractory status epilepticus. Neurology 2003; 60: 332–334.
• 47. Bensalem M.K., Fakhoury T.A.: Topiramate and status epilepticus: report of three cases. Epilepsy Behav. 2003; 4: 757–760.
• 48. Kahriman M., Minecan D., Kutluay E. i wsp.: Efficacy of topiramate in children with refractory status epilepticus. Epilepsia 2003; 44: 1353–1356.
• 49. Stojanova V., Rossetti A.O.: Oral topiramate as an add-on treatment for refractory status epilepticus. Acta Neurol. Scand. 2012; 125: e7–e11.
• 50. Hottinger A., Sutter R., Marsch S. i wsp.: Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study. CNS Drugs 2012; 26: 761–772.
• 51. Synowiec A.S., Yandora K.A., Yenugadhati V. i wsp.: The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res. 2012; 98: 232–237.
• 52. Selai C.E., Trimble M.R., Price M.J. i wsp.: Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs. Curr. Med. Res. Opin. 2005; 21: 733–739.
• 53. Mula M., Trimble M.R., Lhatoo S.D. i wsp.: Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003; 44: 659–663.
• 54. Lee S., Sziklas V., Andermann F. i wsp.: The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003; 44: 339–347.
• 55. Tatum W.O. 4th, French J.A., Faught E. i wsp.: Post-marketing antiepileptic drug survey. Postmarketing experience with topiramate and cognition. Epilepsia 2001; 42: 1134–1140.
• 56. Kanner A.M., Wuu J., Faught E. i wsp.: A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav. 2003; 4: 548–552.
• 57. Philippi H., Boor R., Reitter B.: Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 2002; 43: 744–747.
• 58. Lamb E.J., Stevens P.E., Nashef L.: Topiramate increases biochemical risk of nephrolithiasis. Ann. Clin. Biochem. 2004; 41: 166–169.
• 59. Verrotti A., Scaparrotta A., Agostinelli S. i wsp.: Topiramateinduced weight loss: a review. Epilepsy Res. 2011; 95: 189–199.
• 60. Reiter E., Feucht M., Hauser E. i wsp.: Changes in body mass index during long-term topiramate therapy in pediatric epilepsy patients – a retrospective analysis. Seizure 2004; 13: 491–493.
• 61. McElroy S.L., Hudson J.I., Capece J.A. i wsp.; Topiramate Binge Eating Disorder Research Group: Topiramate for the treatment of binge eating disorder associated with obesity: a placebo- controlled study. Biol. Psychiatry 2007; 61: 1039–1048.
• 62. Ramos E.J., Meguid M.M., Campos A.C., Coelho J.C.: Neuropeptide Y, α-melanocyte-stimulating hormone, and monoamines in food intake regulation. Nutrition 2005; 21: 269–279.
• 63. Giovambattista A., Chisari A.N., Gaillard R.C. i wsp.: Food intake-induced leptin secretion modulates hypothalamo-pituitary- adrenal axis response and hypothalamic Ob-Rb expression to insulin administration. Neuroendocrinology 2000; 72: 341–349.
• 64. York D.A., Singer L., Thomas S. i wsp.: Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000; 16: 967–975.
• 65. Nowak K.W., Pierzchala-Koziec K., Tortorella C. i wsp.: Effects of prolonged leptin infusion on rat pituitary-adrenocortical function. Int. J. Mol. Med. 2002; 9: 61–64.
• 66. Lalonde J., Samson P., Poulin S. i wsp.: Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice. Physiol. Behav. 2004; 80: 415–420.
• 67. Asconapé J.J.: Some common issues in the use of antiepileptic drugs. Semin. Neurol. 2002; 22: 27–39.
• 68. Biton V.: Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003; 17: 781–791.

• Document Type: article